Robert W. Baird reiterated their buy rating on shares of McKesson (NYSE:MCK) in a research note published on Wednesday morning. The firm currently has a $200.00 price objective on the stock.
A number of other research analysts have also recently commented on the company. Needham & Company LLC set a $178.00 target price on McKesson and gave the company a buy rating in a research note on Tuesday, October 24th. Credit Suisse Group reaffirmed an underperform rating and set a $130.00 target price (down previously from $155.00) on shares of McKesson in a research note on Thursday, November 9th. Deutsche Bank started coverage on McKesson in a research note on Monday, December 4th. They set a buy rating and a $175.00 target price on the stock. Royal Bank of Canada reaffirmed a hold rating and set a $170.00 target price on shares of McKesson in a research note on Friday, October 27th. Finally, Zacks Investment Research raised McKesson from a hold rating to a buy rating and set a $177.00 target price on the stock in a research note on Tuesday, December 26th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company’s stock. McKesson currently has a consensus rating of Hold and a consensus price target of $174.85.
Shares of McKesson (NYSE:MCK) opened at $170.36 on Wednesday. McKesson has a 52-week low of $133.82 and a 52-week high of $173.84. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.61 and a current ratio of 1.05. The stock has a market capitalization of $35,515.80, a P/E ratio of 8.08, a price-to-earnings-growth ratio of 1.74 and a beta of 1.23.
McKesson (NYSE:MCK) last issued its quarterly earnings data on Thursday, October 26th. The company reported $3.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.78 by $0.50. McKesson had a return on equity of 24.87% and a net margin of 2.24%. The business had revenue of $52.06 billion for the quarter, compared to the consensus estimate of $51.69 billion. During the same period in the prior year, the business posted $2.94 earnings per share. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. equities research analysts predict that McKesson will post 12.26 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 1st were paid a $0.34 dividend. The ex-dividend date was Thursday, November 30th. This represents a $1.36 annualized dividend and a yield of 0.80%. McKesson’s dividend payout ratio (DPR) is currently 6.45%.
In related news, Chairman John H. Hammergren sold 65,000 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $160.00, for a total value of $10,400,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.20% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the stock. IHT Wealth Management LLC grew its stake in McKesson by 64.2% in the second quarter. IHT Wealth Management LLC now owns 486 shares of the company’s stock worth $1,027,000 after purchasing an additional 190 shares in the last quarter. WFG Advisors LP grew its stake in McKesson by 5.0% in the second quarter. WFG Advisors LP now owns 859 shares of the company’s stock worth $141,000 after purchasing an additional 41 shares in the last quarter. CWH Capital Management Inc. bought a new position in McKesson in the second quarter worth approximately $165,000. Wealthcare Advisory Partners LLC bought a new position in McKesson in the third quarter worth approximately $155,000. Finally, BRYN MAWR TRUST Co bought a new position in McKesson in the second quarter worth approximately $208,000. 87.91% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “McKesson (MCK) Stock Rating Reaffirmed by Robert W. Baird” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/21/mckesson-mck-stock-rating-reaffirmed-by-robert-w-baird.html.
McKesson Corporation is a healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare.
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.